Bladder cancer SNP panel predicts susceptibility and survival
- PMID: 19252927
- PMCID: PMC2763504
- DOI: 10.1007/s00439-009-0645-6
Bladder cancer SNP panel predicts susceptibility and survival
Abstract
Bladder cancer is the fourth most common malignancy in men and the eighth most common in women in western countries. Single nucleotide polymorphisms (SNPs) in genes that regulate telomere maintenance, mitosis, inflammation, and apoptosis have not been assessed extensively for this disease. Using a population-based study with 832 bladder cancer cases and 1,191 controls, we assessed genetic variation in relation to cancer susceptibility or survival. Findings included an increased risk associated with variants in the methyl-metabolism gene, MTHFD2 (OR 1.7 95% CI 1.3-2.3), the telomerase TEP1 (OR 1.8 95% CI 1.2-2.6) and decreased risk associated with the inflammatory response gene variant IL8RB (OR 0.6 95% CI 0.5-0.9) compared to wild-type. Shorter survival was associated with apoptotic gene variants, including CASP9 (HR 1.8 95% CI 1.1-3.0). Variants in the detoxification gene EPHX1 experienced longer survival (HR 0.4 (95% CI 0.2-0.8). These genes can now be assessed in multiple study populations to identify and validate SNPs appropriate for clinical use.
Figures
References
-
- Ahsan H, Thomas DC. Lung cancer etiology: independent and joint eVects of genetics, tobacco, and arsenic. JAMA. 2004;292:3026–3029. - PubMed
-
- Alvarez A, Lokeshwar VB. Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol. 2007;17:341–346. - PubMed
-
- Andrew AS, Nelson HH, Kelsey KT, et al. Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis. 2006;27:1030–1037. - PubMed
-
- Breiman L. Statistical modeling the two cultures. Stat Sci. 2001;16:199–231.
Publication types
MeSH terms
Substances
Grants and funding
- LM009012/LM/NLM NIH HHS/United States
- R01 CA057494/CA/NCI NIH HHS/United States
- ES00002/ES/NIEHS NIH HHS/United States
- CA82354/CA/NCI NIH HHS/United States
- CA121382/CA/NCI NIH HHS/United States
- P30 ES000002/ES/NIEHS NIH HHS/United States
- P42 ES007373/ES/NIEHS NIH HHS/United States
- P20 RR018787/RR/NCRR NIH HHS/United States
- P30 CA023108/CA/NCI NIH HHS/United States
- P42 ES005947/ES/NIEHS NIH HHS/United States
- K07 CA102327/CA/NCI NIH HHS/United States
- R01 LM009012/LM/NLM NIH HHS/United States
- CA099500/CA/NCI NIH HHS/United States
- R03 CA099500/CA/NCI NIH HHS/United States
- R01 CA078609/CA/NCI NIH HHS/United States
- ES007373/ES/NIEHS NIH HHS/United States
- CA102327/CA/NCI NIH HHS/United States
- R03 CA121382/CA/NCI NIH HHS/United States
- CA078609/CA/NCI NIH HHS/United States
- RR018787/RR/NCRR NIH HHS/United States
- CA57494/CA/NCI NIH HHS/United States
- P42 ES05947/ES/NIEHS NIH HHS/United States
- R01 CA082354/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
